Komori
ReproCELL (4978) · FactFull-year earnings update for the research support businessLatest Earnings (2026-08-13): "Advanced"

Research Support Business Segment Turning Profitable

First written in FY2021-Q3. 14 of 20 entries say "Advanced", first in FY2021. Latest entry: 2026-08-13.

20entries
6years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2021 – FY2023AdvancedFY2024-Q2 – FY20252021: 420212022: 320222023: 420232024: 320242025: 220252026: 42026
Same theme, other companies
Growth in the Drug Discovery and Drug Discovery Support BusinessesA theme 4 companies write about · 0 as a headwind · 5 as a tailwind

1 other company's latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-13AdvancedEarnings

    「As a result, revenue was ¥483 million, up 10.3% year on year, and segment profit was ¥20 million, compared with a segment loss of ¥26 million in the same quarter of the previous year.」

    The Research Support business moved from a segment loss in the same period of the previous year to segment profit, marking progress toward profitability.
  2. FY2026Full-year earnings update for the research support businessAnnual report

    「As a result, revenue was ¥1,952 million, down 19.1% year on year, and segment profit was ¥96 million, down 84.5%.」

    The Research Support business remained profitable, but both revenue and segment profit declined from the previous fiscal year, with profit falling from ¥621 million to ¥96 million.
  3. FY2026-H1Update to interim results for the Research Support businessAnnual report

    「As a result, revenue was ¥887 million, down 22.4% year on year, and the segment recorded a loss of ¥22 million, compared with profit of ¥267 million in the same period of the previous year.」

    The Research Support business moved from segment profit of ¥267 million in the same period of the previous year to a segment loss of ¥22 million in the current interim period.
  4. FY2025AdvancedAnnual report

    「As a result, revenue was ¥2,414 million, up 16.1% from the previous fiscal year, and segment profit was ¥621 million, up 39.4%.」

    The Research Support business generated revenue of ¥2,414 million and segment profit of ¥621 million, with both increasing from the previous fiscal year and the level of profitability improving further.
  5. FY2025-H1AdvancedAnnual report

    「As a result, revenue was ¥1,144 million, up 11.6% year on year, and segment profit was ¥267 million, up 53.3% year on year.」

    The Research Support business generated revenue of ¥1,144 million and segment profit of ¥267 million, with both increasing from the same period of the previous year. The segment remained profitable, and its profit level improved.
  6. FY2024AdvancedAnnual report

    「As a result, revenue was ¥2,079 million, up 3.1% from the previous fiscal year, and segment profit was ¥445 million, compared with ¥366 million in the previous fiscal year.」

    The Research Support business generated revenue of ¥2,079 million and segment profit of ¥445 million, with both increasing from the previous fiscal year and the segment remaining profitable.
  7. FY2024-Q3AdvancedAnnual report

    「As a result, revenue was ¥1,512 million, up 11.4% year on year, and segment profit was ¥264 million, up 32.4% year on year.」

    Revenue in the Research Support business increased 11.4% year on year and segment profit increased 32.4%, with the segment remaining profitable.
  8. FY2024-Q2AdvancedAnnual report

    「As a result, revenue was ¥1,025 million, up 13.6% year on year, and segment profit was ¥174 million, up 29.7% year on year.」

    The Research Support business generated revenue of ¥1,025 million and segment profit of ¥174 million, with both revenue and profit increasing year on year and the segment remaining profitable.
  9. FY2024-Q1Quarterly results update for the research support businessAnnual report

    「As a result, revenue was ¥505 million, up 10.4% year on year, and segment profit was ¥81 million, down 2.9% year on year.」

    Revenue in the research support business increased 10.4% year on year, while segment profit was ¥81 million, down 2.9% year on year. The business remained profitable.
  10. FY2023AdvancedAnnual report

    「As a result, revenue was ¥2,017 million, up 46.1% year on year, and segment profit was ¥366 million, compared with ¥135 million in the previous fiscal year.」

    The research support business generated revenue of ¥2,017 million and segment profit of ¥366 million, with revenue and profit increasing from the previous fiscal year. Segment profitability was maintained and profit levels improved further.
  11. FY2023-Q3AdvancedAnnual report

    「As a result, revenue was ¥1,356 million, up 39.2% year on year, and segment profit was ¥199 million, up 123.8% year on year.」

    Segment profit in the research support business increased from ¥89 million in the same period of the previous year to ¥199 million, while revenue rose 39.2% year on year. Segment profitability was maintained and profit levels improved.
  12. FY2023-Q2AdvancedAnnual report

    「As a result, revenue was ¥902 million, up 45.5% year on year, and segment profit was ¥134 million, up 86.2% year on year.」

    The research support business generated revenue of ¥902 million and segment profit of ¥134 million, with revenue and profit increasing year on year and profitability maintained.
  13. FY2023-Q1AdvancedAnnual report

    「As a result, revenue was ¥457 million, up 62.8% year on year, and segment profit was ¥83 million, up 167.2% year on year.」

    The research support business generated revenue of ¥457 million and segment profit of ¥83 million, with revenue and profit increasing year on year and profitability maintained.
  14. FY2022-Q3AdvancedAnnual report

    「As a result, revenue was ¥974 million, up 10.4% year on year, and segment profit was ¥89 million, up 272.9% year on year.」

    The research support business's segment profit increased from ¥23 million in the same period of the previous year to ¥89 million for the nine-month period ended in the third quarter of the current fiscal year, maintaining profitability.
  15. FY2022-Q2AdvancedAnnual report

    「As a result, revenue was ¥620 million, up 9.6% year on year, and segment profit was ¥72 million, up 248.7% year on year.」

    Revenue in the research support business increased 9.6% year on year and segment profit increased 248.7% to ¥72 million.
  16. FY2022-Q1AdvancedAnnual report

    「As a result, revenue was ¥281 million, up 76.1% year on year, and segment profit was ¥31 million, compared with a segment loss of ¥10 million in the same period of the previous year.」

    The research support business turned from a segment loss of ¥10 million in the same period of the previous year to segment profit of ¥31 million in the first quarter of the current fiscal year, maintaining profitability.
  17. FY2021AdvancedAnnual report

    「As a result, revenue was ¥1,200 million, up 7.1% year on year, and segment profit was ¥93 million, compared with a loss of ¥12 million in the previous fiscal year.」

    The research support business turned from a segment loss of ¥12 million in the previous fiscal year to segment profit of ¥93 million in the current fiscal year, achieving a profitable segment for the full year.
  18. FY2021-Q3First statedAnnual report

    「As a result, revenue was ¥882 million, up 6.7% year on year, and segment profit was ¥23 million, compared with a segment loss of ¥76 million in the same quarter of the previous year.」

    The research support business's shift from a segment loss in the same quarter of the previous year to segment profit of ¥23 million for the nine-month period ended in the third quarter of the current fiscal year was identified as a separate theme for the first time.
Moved together

"Persistent losses as upfront investment and R&D expenses precede revenue generation" moved the same way as this thread, in the same document, in 11 of its 20 moves.

11119997★123456
  1. ★This thread
  2. 1Persistent losses as upfront investment and R&D expenses precede revenue generation11×
  3. 2Risk of delayed elimination of accumulated deficits11×
  4. 3Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights9×
  5. 4Exclusive development and marketing of Stemchymal® in Japan9×
  6. 5Development and Supply of an iPS Cell Bank for Clinical Applications9×
  7. 6Funding Needs and Financing Risk Associated with Research and Development and Capital Investment7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet. It last moved in the Earnings of 2026-08-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Research Support Business Segment Turning Profitable | ReproCELL Incorporated (4978) | Komori